Key result
Emerging PAH therapies increasingly focus on inhibiting vascular proliferation and promoting apoptosis alongside established combinations.
Why the study?
Current therapies for pulmonary arterial hypertension have limited effect on vascular remodelling, prompting investigation of novel treatments targeting vascular proliferation and apoptosis.
Answers are grounded in this paper and cite their sources.
The review highlights the evolving therapeutic landscape for pulmonary arterial hypertension, focusing on novel targets for vascular remodeling and combination strategies.
Pulmonary arterial hypertension is characterised by increased pulmonary vascular resistance due to increased vascular tone and structural remodelling of pulmonary vessels. The therapies that are in use so far have been developed to correct endothelial dysfunction and reduce vasomotor tone. These treatments have a limited effect on the remodelling process and, increasingly, the focus is turning to potent strategies for inhibiting vascular proliferation and promoting vascular apoptosis. Multiple novel targets have been uncovered over the last 5 years and several are now in early clinical trials. At present, it is clear that there is no single treatment for the condition. Although this is the case, studies are investigating the role of combining therapies that are already established.
No takes yet. Share an insight, caveat, or question.
Wharton et al. (2007) conducted a review in Pulmonary arterial hypertension. Emerging therapies was evaluated. Emerging therapies for pulmonary arterial hypertension are increasingly focusing on inhibiting vascular proliferation and promoting vascular apoptosis, alongside combining established treatments.
Synapse has enriched 10 related papers. Consider them for comparative context: